Insmed’s gene therapy poised to challenge DMD landscape after IND clearance
Insmed plans to initiate Phase I clinical trials for its INS1201 gene therapy in H1 2025.
Cell & Gene Therapy
Novartis acquires Kate Therapeutics to advance gene therapies
FDA shares additional draft guidance on CGTs
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
Resolution scores $83m to develop macrophage cell therapies
Genespire raises $52m in Series B to trial paediatric gene therapy
The most expensive drugs in the US
Gene therapy: How Veristat cut trial database costs by 30%
